Nanjing, China

Chenxi Du

This inventor holds 1 USPTO granted patent. Top assignee: China Pharmaceutical University. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Chenxi Du in Alzheimer's Disease Treatment

Introduction

Chenxi Du is an innovative inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Alzheimer's disease. His work focuses on developing selective inhibitors that can potentially improve the quality of life for patients suffering from this debilitating condition.

Latest Patents

Chenxi Du holds a patent for a selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof. The patent describes a preparation method and the use of this inhibitor in treating Alzheimer's disease. The invention demonstrates good target activity in vitro, extremely high selectivity, and drug safety. This makes it a promising lead substance for further development in the treatment of moderate to severe Alzheimer's disease.

Career Highlights

Chenxi Du is affiliated with China Pharmaceutical University, where he conducts research and development in the pharmaceutical sciences. His work has garnered attention for its potential impact on Alzheimer's treatment, showcasing his dedication to advancing medical science.

Collaborations

Chenxi Du collaborates with notable colleagues, including Feng Feng and Haopeng Sun. Their combined expertise contributes to the innovative research being conducted at China Pharmaceutical University.

Conclusion

Chenxi Du's contributions to the field of Alzheimer's disease treatment through his innovative patent highlight the importance of targeted therapies in modern medicine. His work exemplifies the potential for scientific advancements to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…